Table 2.

Phase II GOG studies for advanced or recurrent endometrial cancer.

Author, year	Number of patients	Regimena	Molecular target	PFSb (median)	OSc (median)
GOG 181 B [11]	67	Trastuzumab	Her-2/neu	2
GOG 188		Faslodex
GOG 238		WPI ± concurrent
		CDDP
GOG 248		Temsirolimus	mTOR, PTEN
GOG 229 Series
B [12]	27	Thalidomide		1.9	8.3
C[13]	29	Gefitinib	EGFR	4/26 pts PFS	N/A
				>6 months
D	31	Lapatinib	EGFR
E [14]	56	Bevacizumab	VEGF	1.7	6.3
F	28	VEGF-TRAP
G	29	Bevacizumab +
		Temsirolimus
GOG 129 Series
N [15]		Docetaxel		3	10.6
O [16]	27	Pemetrexed		2.7	9.4
P [17]	52	Ixabepilone	Epothilone B	2.9	8.7
Q		Gemcitabine

^aWPI = whole pelvic irradiation.

^bProgression free survival.

^cOverall survival.